Compositions comprising decitabine and tetrahydrouridine and uses thereof
View Patent ↗Compositions comprising decitabine and tetrahydrouridine for the treatment of blood disorders and hematological and solid malignancies are described.
1. A composition for oral administration comprising a therapeutically effective amount of decitabine and tetrahydrouridine, wherein said composition comprises about 1.0 to about 150 mg/m 2 decitabine and about 100 to about 500 mg/m 2 tetrahydrouridine, wherein the tetrahydrouridine is bio-available about 15 to about 180 minutes before the decitabine.
2. The composition of claim 1 wherein said composition comprises about 6 to about 28.4 mg/m 2 decitabine.
3. The composition of claim 1 wherein said composition comprises about 6 to about 10 mg/m 2 decitabine.
4. The composition of claim 1 , wherein the composition is effective to result in a peak decitabine plasma concentration no greater than 0.5 μM in a subject, and wherein the composition is a solid dosage formulation.
5. The composition of claim 1 , wherein the composition is effective to result in a peak decitabine plasma concentration of about 0.1 μM to 0.5 μM in the subject.
6. The composition of claim 1 , wherein the decitabine is present in an amount effective for treating a blood disorder in a subject.
7. The composition of claim 6 , wherein the blood disorder is a hemoglobinopathy or a thalassemia.
8. The composition of claim 1 , wherein the decitabine is present in an amount effective for treating a hematological or solid malignancy in a subject.
9. The composition of claim 8 , wherein the malignancy is selected from the group consisting of leukemia, lymphoma, multiple myeloma, cancer of the brain, cancer of the head, cancer of the neck, cancer of the mouth, cancer of the pharynx, cancer of the esophagus, cancer of the stomach, cancer of the intestine, cancer of the thyroid, cancer of the lungs, cancer of the mediastinum, cancer of the thymus, cancer of the mesothelium, cancer of the peritoneum, cancer of the bone, cancer of the muscle, cancer of the skin, cancer of the prostate, cancer of the breasts, cancer of the ovaries, cancer of the uterus, cancer of the vagina, and an EBV malignancy.
10. The composition of claim 1 , wherein the tetrahydrouridine is bio-available about 30 to about 60 minutes before the decitabine.
11. The composition of claim 1 , wherein the composition is in the form of a capsule or tablet comprising a pharmaceutically acceptable excipient.
12. The composition of claim 11 , wherein the tetrahydrouridine is bio-available about 30 to about 60 minutes before the decitabine.
13. The composition of claim 11 , wherein the tetrahydrouridine is located at the surface of the capsule or tablet, and the decitabine is located within the capsule or tablet.
14. A method for treating a blood disorder in a subject, comprising administering to the subject the composition of claim 1 .
15. The method of claim 14 , wherein the blood disorder is a hemoglobinopathy or a thalassemia.
16. The method of claim 14 , wherein the subject is provided an additional form of therapy.
17. The method of claim 14 , wherein the subject is refractory to or intolerant of treatment with hydroxyurea.
18. A method for treating a hematological or solid malignancy in a subject, comprising administering to the subject the composition of claim 1 .
19. The method of claim 18 , wherein the malignancy is selected from the group consisting of leukemia, lymphoma, multiple myeloma, cancer of the brain, cancer of the head, cancer of the neck, cancer of the mouth, cancer of the pharynx, cancer of the esophagus, cancer of the stomach, cancer of the intestine, cancer of the thyroid, cancer of the lungs, cancer of the mediastinum, cancer of the thymus, cancer of the mesothelium, cancer of the peritoneum, cancer of the bone, cancer of the muscle, cancer of the skin, cancer of the prostate, cancer of the breasts, cancer of the ovaries, cancer of the uterus, and cancer of the vagina.
20. The method of claim 18 , wherein the subject is provided an additional form of therapy.
21. The method of claim 18 , wherein the subject is human.
22. The method of claim 18 , further comprising obtaining the composition.
23. A method for decreasing the inter-individual variation in decitabine pharmacokinetics and/or clinical effects in subjects, comprising administering to the subjects the composition of claim 1 .
24. A method for extending the time-above-threshold concentration for depleting DNMT1 with decitabine in a subject and avoiding DNA-damaging high peak levels of decitabine, comprising administering to the subject the composition of claim 1 .